In this study, we identified CCDC102B via CRISPR/Cas9 screening in vivo and found that it was significantly upregulated in metastatic LNs compared with primary tumors, which led to a poor prognosis in breast cancer patients. This evidence concerns the gene CCDC102B and breast carcinoma.